Kyongbo Pharmaceutical Co., Ltd. (214390) Financial Statements

― Followers

Kyongbo Pharmaceutical Co., Ltd. Financial Overview

Kyongbo Pharmaceutical Co., Ltd.'s market cap is currently ₩129.34B. The company's EPS TTM is ₩208.03; its P/E ratio is 26.01; and it has a dividend yield of 0.92%. Kyongbo Pharmaceutical Co., Ltd. is scheduled to report earnings on August 14, 2026, and the estimated EPS forecast is ₩―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 264.10B	₩ 238.56B	₩ 216.36B	₩ 196.26B	₩ 170.66B
Gross Profit	₩ 97.82B	₩ 82.42B	₩ 63.08B	₩ 44.42B	₩ 33.13B
Operating Income	₩ 3.52B	₩ 10.45B	₩ 5.54B	₩ 1.39B	₩ -6.62B
EBITDA	₩ 16.72B	₩ 21.60B	₩ 17.24B	₩ 12.78B	₩ 4.21B
Net Income	₩ 182.29M	₩ 4.64B	₩ 2.97B	₩ 610.59M	₩ -7.50B
Balance Sheet
Cash & Short-Term Investments	₩ 8.05B	₩ 6.13B	₩ 5.35B	₩ 7.22B	₩ 4.29B
Total Assets	₩ 319.24B	₩ 283.89B	₩ 266.31B	₩ 240.54B	₩ 236.98B
Total Debt	₩ 126.67B	₩ 91.43B	₩ 75.94B	₩ 64.51B	₩ 56.59B
Net Debt	₩ 119.44B	₩ 87.30B	₩ 71.46B	₩ 58.16B	₩ 52.30B
Total Liabilities	₩ 173.80B	₩ 137.73B	₩ 121.92B	₩ 96.84B	₩ 91.28B
Stockholders' Equity	₩ 145.44B	₩ 146.15B	₩ 144.38B	₩ 143.70B	₩ 145.70B
Cash Flow
Free Cash Flow	₩ -34.08B	₩ -13.03B	₩ -6.03B	₩ -3.06B	₩ -355.61M
Operating Cash Flow	₩ 7.46B	₩ 149.12M	₩ 4.84B	₩ 10.13B	₩ 17.97B
Investing Cash Flow	₩ -37.98B	₩ -14.63B	₩ -14.27B	₩ -14.88B	₩ -16.17B
Financing Cash Flow	₩ 33.76B	₩ 13.87B	₩ 7.16B	₩ 6.59B	₩ -9.22B

Currency in KRW

Kyongbo Pharmaceutical Co., Ltd. Earnings and Revenue History

Income Statement >

Kyongbo Pharmaceutical Co., Ltd. Debt to Assets

Balance Sheet >

Kyongbo Pharmaceutical Co., Ltd. Cash Flow

Cash Flow >

Kyongbo Pharmaceutical Co., Ltd. Forecast EPS vs Actual EPS

Earnings >